ENANTA PHARMACEUTICALS, INC Net Fee Amt
ENANTA PHARMACEUTICALS, INC (ENTA) had Net Fee Amt of $3.29 thousand as of 2026-05-11, per its S-8 filed 2026-05-13.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-13
- 2026-05-11: Net Fee Amt $3.29K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-11 | $3.29K S-8 · filed 2026-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |